These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22203591)

  • 41. [In vitro activity of doripenem and other carbapenems against Pseudomonas aeruginosa].
    Nicola F; García Ramírez D; Arduino S; Di Chiara M; Smayevsky J
    Rev Argent Microbiol; 2010; 42(3):193-8. PubMed ID: 21186673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
    Cook PP; Gooch M; Rizzo S
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5597-601. PubMed ID: 21968357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
    Anan N; Toba S; Ito A; Nakamura R; Tsuji M
    Jpn J Antibiot; 2011 Aug; 64(4):203-16. PubMed ID: 22066345
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
    Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
    Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
    J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
    Crandon JL; Luyt CE; Aubry A; Chastre J; Nicolau DP
    J Antimicrob Chemother; 2016 Sep; 71(9):2534-7. PubMed ID: 27272723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
    J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa.
    Hermes DM; Pormann Pitt C; Lutz L; Teixeira AB; Ribeiro VB; Netto B; Martins AF; Zavascki AP; Barth AL
    J Med Microbiol; 2013 Aug; 62(Pt 8):1184-1189. PubMed ID: 23699064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of doripenem.
    Sahm D
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Activity of doripenem against anaerobic bacteria].
    Dubreuil L; Neut C; Mahieux S; Muller-Serieys C; Jean-Pierre H; Marchandin H; Soussy CJ; Miara A
    Pathol Biol (Paris); 2011 Apr; 59(2):102-7. PubMed ID: 20537808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study.
    Gales AC; Azevedo HD; Cereda RF; Girardello R; Xavier DE;
    Braz J Infect Dis; 2011; 15(6):513-20. PubMed ID: 22218508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
    Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
    Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
    Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.